Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review.
Allergy Asthma Clin Immunol
; 17(1): 112, 2021 Oct 26.
Article
in En
| MEDLINE
| ID: mdl-34702371
ABSTRACT
BACKGROUND:
Treatment with immune checkpoint inhibitors has revolutionized cancer treatment over the past several years. Despite their clinical benefits, a wide range of immune-mediated toxicities can be observed including hematological toxicities. Although, the majority can easily be managed, immune-mediated adverse events rarely can be severe and difficult to approach. Herein, we are reporting a case of very severe aplastic anemia secondary to ipilimumab (I) and nivolumab (N) treatment that failed various treatment including intensive immune suppressive therapy. CASE PRESENTATION We described a case of a 45-year old white male, heavy smoker presented to the clinic complaining of left flank pain. He was found to have a metastatic renal cell carcinoma for which he was treated with dual immunotherapy and later complicated by severe immune related adverse events. The patient later died after failing intensive immune suppressive therapy.CONCLUSION:
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with variant malignancies. Yet, lethal adverse events can occur in rare cases. It is our duty, as physicians, to remain alert and cautious.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Allergy Asthma Clin Immunol
Year:
2021
Document type:
Article
Affiliation country:
Lebanon